These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21392723)

  • 1. Continuation of mortality reduction after the end of randomized therapy in clinical trials of lipid-lowering therapy.
    Kostis WJ; Moreyra AE; Cheng JQ; Dobrzynski JM; Kostis JB
    J Clin Lipidol; 2011; 5(2):97-104. PubMed ID: 21392723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Views on lipid lowering. JUPITER seems to be bypassed.
    Murray SW
    BMJ; 2010 Oct; 341():c5835. PubMed ID: 20959303
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive lipid lowering therapy in the era of surrogate endpoints.
    Silverman MG; Blaha MJ; Blumenthal RS
    Cardiol Rev; 2011; 19(1):17-22. PubMed ID: 21135598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [ALLHAT [Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial]].
    Tomiyama H; Doba N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():393-7. PubMed ID: 11347101
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical implications of the BARI 2D and COURAGE trials of coronary artery disease.
    Kuller LH
    Coron Artery Dis; 2010 Nov; 21(7):391-6. PubMed ID: 20634693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry.
    Melloni C; Shah BR; Ou FS; Roe MT; Smith SC; Pollack CV; Ohman M; Gibler WB; Peterson ED; Alexander KP
    Am Heart J; 2010 Dec; 160(6):1121-9, 1129.e1. PubMed ID: 21146667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized clinical trials and recent patterns in the use of statins.
    Wang TJ; Stafford RS; Ausiello JC; Chaisson CE
    Am Heart J; 2001 Jun; 141(6):957-63. PubMed ID: 11376310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fenofibrate].
    Yamashita T; Nakamura H
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():618-24. PubMed ID: 11347142
    [No Abstract]   [Full Text] [Related]  

  • 10. Lipid lowering: what and when to monitor.
    Criqui MH; Golomb BA
    Lancet; 2008 Aug; 372(9638):516-7. PubMed ID: 18707970
    [No Abstract]   [Full Text] [Related]  

  • 11. [Helsinki Heart Study].
    Sekiya M; Ishibashi S
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():404-9. PubMed ID: 11347103
    [No Abstract]   [Full Text] [Related]  

  • 12. Transferring patients with ST-segment elevation myocardial infarction for mechanical reperfusion: a meta-regression analysis of randomized trials.
    De Luca G; Biondi-Zoccai G; Marino P
    Ann Emerg Med; 2008 Dec; 52(6):665-76. PubMed ID: 19027496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
    Pérez A
    Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevention of cardiovascular disease utilizing fibrates--a pooled meta-analysis.
    Loomba RS; Arora R
    Am J Ther; 2010; 17(6):e182-8. PubMed ID: 20535009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
    Sobieraj DM; White CM; Coleman CI
    Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin use in a "real-world" clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial.
    Koren MJ
    Am J Med; 2005 Dec; 118 Suppl 12A():16-21. PubMed ID: 16356803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipids, lipid-lowering therapy and diabetes complications.
    Valensi P; Picard S
    Diabetes Metab; 2011 Feb; 37(1):15-24. PubMed ID: 21126902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality after catheter ablation for atrial fibrillation compared with antiarrhythmic drug therapy. A meta-analysis of randomized trials.
    Dagres N; Varounis C; Flevari P; Piorkowski C; Bode K; Rallidis LS; Tsougos E; Leftheriotis D; Sommer P; Hindricks G; Kremastinos DT
    Am Heart J; 2009 Jul; 158(1):15-20. PubMed ID: 19540387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]].
    Yoshino G; Hirano T; Kazumi T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():433-5. PubMed ID: 11347109
    [No Abstract]   [Full Text] [Related]  

  • 20. [Stroke prevention by statins].
    Sawada N; Itoh H; Nakao K
    Nihon Rinsho; 2002 May; 60(5):993-1001. PubMed ID: 12030004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.